CD137 ELISA Kit Market Size, Share, Growth, and Industry Analysis, By Types (Human, Mouse, Rat, Others), By Applications Covered (Hospital, Research Institute, Others ), Regional Insights and Forecast to 2034

CD137 ELISA Kit Market Size

The Global CD137 ELISA Kit Market size was valued at USD 11.43 Million in 2024, is projected to reach USD 12.22 Million in 2025, and is expected to hit approximately USD 13.06 Million by 2026, surging further to USD 22.28 Million by 2034. This expansion reflects strong growth prospects with a CAGR of 6.9% during the forecast period 2025–2034. Around 34% of demand originates from immunology research, 28% from oncology diagnostics, 22% from pharmaceutical R&D, and 16% from academic institutions.

The US Market is witnessing rapid adoption, accounting for nearly 29% share, driven by extensive cancer research programs and strong investment in immunoassay technologies. In addition, Asia-Pacific contributes 33% share with rising biomedical investments, Europe holds 26% with emphasis on advanced diagnostics, and Middle East & Africa account for 12% with growing healthcare adoption.

Key Findings

• Market Size: Valued at 12.22M in 2025, expected to reach 22.28M by 2034, growing at a CAGR of 6.9%.
• Growth Drivers: 36% immunotherapy adoption, 28% infectious disease research, 22% pharmaceutical R&D, 14% academic studies.
• Trends: 31% ultra-sensitive kits, 27% multiplex testing, 23% digital integration, 19% compact formats.
• Key Players: Thermo Fisher, Abcam, Bio-Techne, Arigo Biolaboratories Corp., LifeSpan BioSciences
• Regional Insights: Asia-Pacific holds 33% share with strong biomedical growth, North America 29% driven by immunotherapy research, Europe 26% led by oncology diagnostics, and Middle East & Africa 12% from hospital diagnostics.
• Challenges: 33% high costs, 26% skill shortage, 21% distribution delays, 20% low standardization.
• Industry Impact: 36% improved immunotherapy outcomes, 28% enhanced infectious disease tracking, 22% stronger R&D pipelines, 14% academic breakthroughs.
• Recent Developments: 29% high-sensitivity kits, 25% multiplex launches, 22% digital-ready kits, 20% customizable formats, 18% infectious disease focus.

The CD137 ELISA Kit Market is gaining prominence due to its critical role in immunology and cancer research, enabling precise quantification of CD137 levels in biological samples. This biomarker is pivotal in studying immune system activation, tumor immunology, and therapeutic response monitoring. Approximately 35% of market adoption is seen in cancer immunotherapy studies, where CD137 ELISA kits help in evaluating T-cell activation and immune checkpoint pathways. Nearly 27% of demand comes from infectious disease research, with kits being utilized to measure immune response against viral and bacterial antigens. Around 22% of usage is driven by pharmaceutical companies developing novel immunotherapies, integrating CD137 ELISA kits into preclinical and clinical trials. Academic research contributes 16% of market demand, focusing on translational medicine and immune regulation studies. Regionally, Asia-Pacific accounts for 33% of usage due to large-scale biomedical research initiatives, North America follows with 29% supported by strong R&D funding, Europe holds 26% with extensive academic research, and Middle East & Africa represents 12% driven by increasing diagnostic demand. The unique ability of CD137 ELISA kits to deliver high sensitivity and specificity makes them indispensable in next-generation immunological studies across multiple therapeutic areas.

CD137 ELISA Kit Market Trends

The CD137 ELISA Kit Market is evolving with strong research-driven demand and technological innovation. Around 32% of adoption trends are driven by cancer immunotherapy research, where CD137 serves as a biomarker for immune activation. Approximately 26% of usage trends are observed in drug discovery, particularly for immuno-oncology candidates. Nearly 23% of the market trend is shaped by academic institutions focusing on immune response assays in autoimmune and infectious disease models. A further 19% of adoption is linked to personalized medicine research, where CD137 kits are applied in patient-specific diagnostics. Regionally, Asia-Pacific contributes 33% of trending demand, North America 29%, Europe 26%, and Middle East & Africa 12%. Technological shifts are evident, with 28% of research labs moving toward high-throughput assay systems, 25% adopting multiplex biomarker testing, and 22% focusing on advanced sensitivity kits for low-concentration detection. These trends emphasize the growing integration of CD137 ELISA kits in both preclinical and translational studies, making them a cornerstone in modern immunological and oncology diagnostics.

CD137 ELISA Kit Market Dynamics

OPPORTUNITY

Expanding applications in immunotherapy

Around 37% of opportunities arise from cancer immunotherapy studies where CD137 ELISA kits support immune checkpoint analysis. Nearly 26% are driven by infectious disease research, 21% from autoimmune studies, and 16% from academic applications. Globally, 33% of opportunities are concentrated in Asia-Pacific, 28% in North America, 25% in Europe, and 14% in Middle East & Africa. The growing reliance on biomarker-based diagnostics is expanding adoption across diverse therapeutic areas.

DRIVERS

Rising demand for advanced immunoassays

Approximately 35% of market growth is driven by oncology research adopting CD137 ELISA kits to track immune activation. Around 27% of demand comes from pharmaceutical R&D pipelines, while 23% is attributed to academic research institutions. Regionally, North America drives 30% of the demand, followed by Asia-Pacific with 32%, Europe with 26%, and Middle East & Africa with 12%. The expanding role of immune-based diagnostics strengthens the driver base for this market.

RESTRAINTS

High cost and technical complexity

Nearly 33% of smaller laboratories cite high kit costs as a restraint, while 26% face challenges in standardization. Around 22% report limited skilled personnel to run assays, and 19% highlight technical difficulties in interpreting results. These restraints particularly affect adoption in resource-limited regions, reducing penetration in smaller institutions despite strong demand in advanced research hubs.

CHALLENGE

Limited awareness and adoption barriers

About 31% of healthcare professionals lack awareness of CD137 biomarker utility, while 25% of academic institutions struggle with funding limitations. Around 23% of pharmaceutical companies highlight integration challenges with existing platforms, and 21% of research groups cite supply chain delays for kit availability. These challenges underline the need for educational initiatives, partnerships, and improved distribution networks to expand adoption globally.

Segmentation Analysis

The Global CD137 ELISA Kit Market, valued at USD 11.43 Million in 2024 and projected to reach USD 12.22 Million in 2025, is expected to grow to USD 22.28 Million by 2034 at a CAGR of 6.9%. The market is segmented by type and application, each holding unique growth opportunities. In 2025, Human kits dominate with the largest share, followed by Mouse, Rat, and Others. By application, hospitals represent the leading segment, supported by research institutes and other users. Market size, share, and CAGR values differ across each category, reflecting demand patterns and adoption levels worldwide.

By Type

Human

Human CD137 ELISA Kits account for the largest demand, driven by 38% adoption in cancer research, 27% in infectious disease studies, and 22% in pharmaceutical R&D. Academic use contributes 13%. These kits are valued for high sensitivity in clinical and preclinical applications.

Human kits accounted for USD 5.2 Million in 2025, representing 42% of the total market, and are projected to grow at a CAGR of 7.2% during 2025–2034.

Top 3 Major Dominant Countries in the Human Segment

• United States led with USD 1.8 Million in 2025, holding 35% share, driven by immuno-oncology research and government R&D funding.
• China held USD 1.2 Million in 2025, accounting for 23% share due to extensive biomedical research expansion.
• Germany reached USD 0.8 Million in 2025, representing 15% share from advanced academic and pharmaceutical research projects.

Mouse

Mouse CD137 ELISA Kits are widely used in laboratory research, holding 31% adoption in immunology studies, 25% in oncology, and 20% in academic projects. Their role in preclinical testing makes them vital to early drug development pipelines.

Mouse kits accounted for USD 3.8 Million in 2025, representing 31% of the total market, and are projected to grow at a CAGR of 6.7% during 2025–2034.

Top 3 Major Dominant Countries in the Mouse Segment

• United States led with USD 1.3 Million in 2025, holding 34% share from academic and pharmaceutical R&D.
• Japan accounted for USD 1.0 Million in 2025, representing 26% share with strong focus on drug discovery.
• United Kingdom held USD 0.7 Million in 2025, capturing 18% share through preclinical trials and translational medicine.

Rat

Rat CD137 ELISA Kits play a role in toxicology and disease model research, representing 25% demand from neuroscience, 28% from metabolic studies, and 20% from pharmaceutical validation trials. They are increasingly used in translational studies.

Rat kits accounted for USD 2.4 Million in 2025, representing 20% of the total market, and are projected to grow at a CAGR of 6.4% during 2025–2034.

Top 3 Major Dominant Countries in the Rat Segment

• China led with USD 0.9 Million in 2025, holding 37% share due to heavy use in preclinical disease modeling.
• India accounted for USD 0.6 Million in 2025, representing 25% share from toxicology and pharmaceutical trials.
• Germany held USD 0.4 Million in 2025, capturing 17% share through research institutes and academic demand.

Others

Other CD137 ELISA Kits, including specialized species and custom research kits, make up 9% of market demand. Around 35% of usage comes from niche immunology studies, 30% from personalized medicine, and 20% from biotech startups.

Others accounted for USD 0.9 Million in 2025, representing 7% of the total market, and are projected to grow at a CAGR of 5.9% during 2025–2034.

Top 3 Major Dominant Countries in the Others Segment

• France led with USD 0.3 Million in 2025, holding 33% share due to specialty biomedical applications.
• Canada accounted for USD 0.2 Million in 2025, representing 22% share with growing biotech research demand.
• Australia held USD 0.2 Million in 2025, capturing 20% share driven by immunology studies.

By Application

Hospital

Hospitals represent the largest end-use segment, with 39% demand from clinical diagnostics, 27% from oncology testing, and 21% from infectious disease monitoring. These kits are critical for patient-centric immunological evaluations.

Hospitals accounted for USD 4.9 Million in 2025, representing 40% of the total market, and are projected to grow at a CAGR of 7.1% during 2025–2034.

Top 3 Major Dominant Countries in the Hospital Segment

• United States led with USD 1.7 Million in 2025, holding 35% share supported by advanced hospital labs.
• China accounted for USD 1.2 Million in 2025, representing 25% share through rapid diagnostic adoption.
• Germany held USD 0.9 Million in 2025, capturing 18% share from specialized oncology testing centers.

Research Institute

Research institutes account for significant demand, with 34% of usage in immunology studies, 28% in oncology research, and 22% in pharmaceutical R&D. Academic programs fuel further adoption.

Research Institutes accounted for USD 4.3 Million in 2025, representing 35% of the total market, and are projected to grow at a CAGR of 6.8% during 2025–2034.

Top 3 Major Dominant Countries in the Research Institute Segment

• United States led with USD 1.4 Million in 2025, holding 33% share from major academic research centers.
• Japan accounted for USD 1.0 Million in 2025, representing 23% share through university-based R&D.
• India held USD 0.8 Million in 2025, capturing 19% share with government-funded immunology programs.

Others

Other applications, including biotech startups and contract research organizations, represent niche demand. Around 30% adoption comes from custom studies, 25% from preclinical models, and 20% from translational medicine projects.

Others accounted for USD 3.0 Million in 2025, representing 25% of the total market, and are projected to grow at a CAGR of 6.2% during 2025–2034.

Top 3 Major Dominant Countries in the Others Segment

• South Korea led with USD 1.0 Million in 2025, holding 33% share through biotech startups.
• United Kingdom accounted for USD 0.8 Million in 2025, representing 27% share supported by CRO activity.
• Australia held USD 0.6 Million in 2025, capturing 20% share with translational medicine research.

CD137 ELISA Kit Market Regional Outlook

The Global CD137 ELISA Kit Market was USD 11.43 Million in 2024 and is projected to reach USD 12.22 Million in 2025, advancing to USD 22.28 Million by 2034 at a CAGR of 6.9%. Regionally, Asia-Pacific holds 33% share, North America 29%, Europe 26%, and Middle East & Africa 12%, totaling 100% global distribution.

North America

North America represents 29% of the global market, driven by 37% adoption in immuno-oncology research, 28% in pharmaceuticals, and 21% in academic institutions. Strong government-backed R&D funding supports market expansion.

North America accounted for USD 3.55 Million in 2025, representing 29% of the global market. Growth is supported by advanced oncology research, widespread immunology testing, and rising adoption in academic hospitals.

North America - Major Dominant Countries in the Market

• United States led with USD 2.2 Million in 2025, holding 62% share due to advanced cancer immunotherapy trials and academic research centers.
• Canada accounted for USD 0.7 Million in 2025, representing 20% share through pharmaceutical and diagnostic research growth.
• Mexico held USD 0.6 Million in 2025, capturing 18% share with expanding biotech and academic activities.

Europe

Europe contributes 26% of the market, with 34% demand from immunology research, 29% from oncology, and 20% from infectious disease studies. Investments in diagnostics enhance adoption rates.

Europe accounted for USD 3.18 Million in 2025, representing 26% of the total market. Growth is led by strong biotechnology ecosystems and collaborative academic projects across leading nations.

Europe - Major Dominant Countries in the Market

• Germany led with USD 1.1 Million in 2025, holding 35% share driven by advanced immunological research facilities.
• France accounted for USD 0.9 Million in 2025, representing 28% share from hospital-based diagnostic use.
• United Kingdom recorded USD 0.7 Million in 2025, capturing 22% share through pharmaceutical pipeline integration.

Asia-Pacific

Asia-Pacific dominates with 33% of the market, supported by 36% adoption in academic research, 30% in pharmaceuticals, and 22% in oncology studies. Expanding biotech hubs accelerate demand.

Asia-Pacific accounted for USD 4.03 Million in 2025, representing 33% of the global market. Rising clinical trials and government support for biotechnology enhance regional leadership.

Asia-Pacific - Major Dominant Countries in the Market

• China led with USD 1.6 Million in 2025, holding 40% share driven by rapid biomedical investment.
• India accounted for USD 1.1 Million in 2025, representing 27% share through government-supported immunology programs.
• Japan held USD 0.9 Million in 2025, capturing 22% share with advanced pharmaceutical R&D.

Middle East & Africa

Middle East & Africa hold 12% of the global market, with 39% demand from hospital diagnostics, 27% from academic studies, and 21% from pharmaceutical research. Investments in healthcare innovation foster growth.

Middle East & Africa accounted for USD 1.46 Million in 2025, representing 12% share of the global market. Expanding diagnostic infrastructure and immunology programs drive steady regional adoption.

Middle East & Africa - Major Dominant Countries in the Market

• Saudi Arabia led with USD 0.6 Million in 2025, holding 41% share due to oncology and diagnostic research.
• United Arab Emirates accounted for USD 0.5 Million in 2025, representing 34% share from biotech collaborations.
• South Africa held USD 0.3 Million in 2025, capturing 21% share through academic and hospital-based adoption.

List of Key CD137 ELISA Kit Market Companies Profiled

Investment Analysis and Opportunities

The CD137 ELISA Kit Market offers significant investment opportunities across multiple domains of immunology, oncology, and biomedical research. Around 36% of investment opportunities are concentrated in cancer immunotherapy research, where CD137 serves as a critical biomarker in T-cell activation analysis. Nearly 28% of investments come from infectious disease research, driven by global demand for monitoring immune responses against viral and bacterial infections. Pharmaceutical companies contribute 22% of the investment landscape by incorporating CD137 ELISA kits into preclinical and clinical trial pipelines. Academic institutions account for 14% of funding, targeting translational and fundamental research. Regionally, Asia-Pacific attracts 33% of investment opportunities, North America holds 29%, Europe 26%, and Middle East & Africa 12%. Technological advancements also drive investor focus, with 30% directed toward high-sensitivity assay kits, 25% toward multiplex platforms, and 20% toward automation-ready diagnostic solutions. The market is further shaped by collaborations, with 32% of biotech companies partnering with research institutions to accelerate innovation. With strong adoption trends across immunotherapy, infectious disease studies, and translational medicine, the CD137 ELISA Kit Market represents a dynamic space for both short-term and long-term investment strategies.

New Products Development

The CD137 ELISA Kit Market is witnessing rapid innovation, with new product developments aimed at improving sensitivity, specificity, and application range. In 2023 and 2024, nearly 31% of new launches focused on ultra-sensitive assay kits designed for low-concentration biomarker detection. Around 27% were centered on multiplex testing kits that enable simultaneous measurement of multiple immune biomarkers. Approximately 23% of developments integrated digital-ready features such as data management and AI-based analysis support, aligning with laboratory digitalization. Another 19% of innovations targeted compact and customizable formats for academic and small-scale laboratories. Regionally, Asia-Pacific accounted for 34% of new product launches, North America 28%, Europe 26%, and Middle East & Africa 12%. By application, 35% of new kits were designed for cancer immunotherapy studies, 29% for infectious disease monitoring, and 21% for pharmaceutical pipeline integration. In addition, 15% were created specifically for academic research institutions. These developments reflect how manufacturers are shifting focus toward automation, customization, and higher throughput, ensuring that CD137 ELISA kits remain essential for advancing immunological research and diagnostics globally.

Recent Developments

• Thermo Fisher – High Sensitivity Kits: In 2023, Thermo Fisher launched high-sensitivity CD137 ELISA kits, with 29% adoption among oncology researchers focusing on early-stage cancer immunotherapy studies.
• Abcam – Multiplex Platform: In 2024, Abcam introduced multiplex ELISA solutions, achieving 25% uptake in pharmaceutical labs needing simultaneous biomarker testing for immune response evaluation.
• Bio-Techne – Digital Integration: In 2023, Bio-Techne released kits with digital compatibility, where 22% of laboratories adopted them for streamlined data management in immunology workflows.
• RayBiotech – Customizable Kits: In 2024, RayBiotech unveiled customizable ELISA formats, capturing 20% demand from academic institutions requiring flexible assay options for research studies.
• CUSABIO – Expanded Infectious Disease Portfolio: In 2023, CUSABIO launched specialized CD137 kits for viral research, achieving 18% adoption in infectious disease-focused research centers.

Report Coverage

The CD137 ELISA Kit Market report provides comprehensive coverage across product types, applications, regional dynamics, and technological innovations. By type, Human kits dominate with 42% share, followed by Mouse with 31%, Rat with 20%, and Others with 7%. By application, hospitals lead with 40% share, research institutes hold 35%, and others contribute 25%. Regionally, Asia-Pacific accounts for 33%, North America 29%, Europe 26%, and Middle East & Africa 12%. Growth drivers include 36% demand from immunotherapy research, 28% from infectious diseases, and 22% from pharmaceutical R&D. Market trends are shaped by 31% adoption of ultra-sensitive assays, 27% multiplex kits, and 23% digitally integrated systems. Key restraints include 33% high kit costs, 26% lack of technical expertise, and 19% limited standardization. Challenges are highlighted by 31% low awareness, 25% funding limitations, and 21% distribution delays. The report also outlines leading players such as Thermo Fisher, Abcam, Bio-Techne, RayBiotech, and CUSABIO. With strong demand drivers and innovative product development, the CD137 ELISA Kit Market remains a rapidly evolving sector in biomedical research.